13 July 2022: Clinical Research
Serum Calprotectin – a NET Product – as a Biomarker of Disease Activity in Patients with Systemic Lupus Erythematosus: A Single-Center Case-Control Study from Poland
Iwona Homa-Mlak 1ACDEF* , Marcin Mazurek 1BCEF , Aleksandra Majdan 1DEF , Radosław Mlak 1ACDE , Maria Majdan 2ADEF , Teresa Mełecka-Massalska 1ADEFDOI: 10.12659/MSM.936534
Med Sci Monit 2022; 28:e936534
Table 4 Correlation between selected clinical and laboratory factors and calprotectin.
| Variable | n | rho | p |
|---|---|---|---|
| Age (years) | 59 | −0.146 | 0.2664 |
| Duration of the disease (years) | 58 | 0.0388 | 0.7695 |
| SLEDAI – Mild vs moderate and severe | 59 | 0.167 | 0.2056 |
| SLEDAI – Mild and moderate vs severe | 59 | 0.0523 | 0.6942 |
| RBC [10/μl] | 59 | −0.122 | 0.3515 |
| HGB [g/dl] | 59 | −0.0108 | 0.9343 |
| WBC [10/μl] | 59 | −0.236 | 0.0726 |
| NEUTR [10/μl] | 59 | −0.171 | 0.1934 |
| LYM [10/μl] | 59 | −0.227 | 0.0833 |
| PLT [10/μl] | 59 | −0.114 | 0.3867 |
| ESR [mm/h] | 58 | −0.122 | 0.3562 |
| CRP [mg/l] | 59 | 0.0625 | 0.6342 |
| Total protein [g/dl] | 41 | 0.259 | 0.1016 |
| Creatinine [mg/dl] | 59 | −0.223 | 0.0899 |
| GFR [ml/min/1.73 m] | 59 | 0.130 | 0.5435 |
| dsDNA | 59 | 0.325 | 0.0277* |
| C3 | 59 | −0.429 | 0.0012* |
| C4 | 28 | −0.291 | 0.1375 |
| IgG [mg/dl] | 23 | 0.395 | 0.0637 |
| IgM [mg/dl] | 23 | 0.0356 | 0.8674 |
| IgA [mg/dl] | 26 | 0.0005 | 0.9982 |
| * Statistically significant results. C3 – complement component 3;C4 – complement component 4; CRP – C reactive protein; dsDNA – double-stranded DNA; GFR – glomerular filtration rate; HGB – haemoglobin; IgA – immunoglobulin A; IgG – immunoglobulin G; IgM – immunoglobulin M; LYM – lymphocytes; n – number; NEUTR – neutrophils; ESR – erythrocyte sedimentation rate; PLT – platelets; RBC – red blood cells; SLEDAI – Systemic Lupus Erythematosus Disease Activity Indexl WBC – white blood cells. | |||